|
Sign In to gain access to subscriptions and/or personal tools.
|
Macrovascular Complications of Diabetes Mellitus
Donald S. Nuzum, PharmD*
and
Tonja Merz, PharmD
* To whom correspondence should be addressed. E-mail: dnuzum{at}wingate.edu.
 |
Abstract |
|---|
Adults with diabetes mellitus frequently develop macrovascular complications. Vascular disease is a frequent cause of morbidity and mortality among patients with diabetes. Diabetes and vascular diseases remain among the most common causes of death in the United States. A number of clinical trials and practice guidelines have been published addressing the management of macrovascular complications. The cornerstone of preventing or delaying the progression of macrovascular complications of diabetes is aggressive management of hypertension and cholesterol. Angiotensin-converting enzyme inhibitors have proven effective in managing hypertension and avoiding other complications of diabetes. The body of evidence for angiotensin receptor blockers is growing in this area as well. Statins have been repeatedly proven to be the first-line agents in the management of dyslipidemia. Lifestyle modification strategies and antiplatelet therapy also remain essential. This review will focus on the role of newer diagnostic techniques, clinical trial evidence, and appropriate pharmacotherapy for macrovascular complications of diabetes.
First published on January 5, 2009, doi:10.1177/0897190008326444
Journal of Pharmacy Practice 2009;22:135.
A more recent version of this article appeared on April 1, 2009
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
